Login to Your Account



Regulatory NEWS

HONG KONG – As part of its efforts to continue reforming China's medical system, the National Health and Family Planning Commission (NHFPC) slashed the price of three top-selling drugs of both foreign and domestic companies by more than half.

As an FDA advisory committee prepares for a double header this week on two fixed-combination diabetes drugs, the agency seems to be balking a bit at the match-up of a basal insulin product that, when used alone, has a wide effective dose range with a GLP-1 receptor agonist that has only one or two recommended effective doses.

BEIJING – China is working on an improved naming system for biologics and biosimilars to better ensure drug safety and good drug administration, according to national authorities. And the system would bring the country closer to internationally recognized naming rules.

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: